Zealand's Lixisenatide Hits Mark in Phase III Combo Trial Oct. 6, 2010 By Cormac Sheridan Lixisenatide, the Type II diabetes molecule discovered by Zealand Pharma A/S, met the primary endpoint in the first Phase III combination trial. (BioWorld International)Read More
RSS